Comparing two drug combos for recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have nasopharyngeal cancer that has come back or spread to other parts of your body.
- You cannot have had any prior chemotherapy or other cancer treatment for the recurrent or metastatic disease. (Previous chemo or radiation as part of your first treatment is okay if the cancer came back more than 6 months later.)
- You must be between 18 and 75 years old.
- You must be in generally good health (able to do daily activities with little or no help) and have adequate blood counts, liver, and kidney function.
- You must have at least one tumor that can be measured on a scan and has not been recently treated with local therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug tislelizumab with chemotherapy for people whose nasopharyngeal cancer has spread to the bones. It may be an option if you have not had prior treatment for advanced disease.
This trial tests a combination of two drugs—an investigational antibody that targets cancer cells (MRG003) and a chemotherapy pill (capecitabine)—along with an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back but hasn't spread. The goal is to see if this approach can help control the cancer.
This study tests a new combination for people whose nasopharyngeal cancer has returned in the same area and cannot be removed by surgery. The treatment combines a targeted drug (becotatug vedotin), an immunotherapy (PD-1 antibody), and radiation to try to shrink or control the cancer.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.